Comparative study between weekly dose of 50mg of Mifepristone and daily dose of 25 mg Mifepristone in medical management of uterine fibroid

Comparative study between weekly dose of 50mg Mifepristone and daily dose of 25 mg Mifepristone in medical management of UTERINE FIBROID

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/02/040442

Enrollment

Registered

2022-02-18

Start date

Unknown

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N938- Other specified abnormal uterine and vaginal bleeding

Interventions

Intervention1: T.MIFEPRISTONE 50mg: One tablet per week for 3months Control Intervention1: T.MIFEPRISTONE 25mg: Once a day for 3months

Eligibility

Inclusion criteria

Inclusion criteria: Women of age group 30-45 Women with symptomatic fibroid Fibroid size 3-5cm Without endometrial hyperplasia

Exclusion criteria

Exclusion criteria: Uterine size more than 12weeks Associated cervical or tubal lesions Pregnancy Fibroid with severe anemia Hepatic and renal dysfunction Endometrial hyperplasia

Design outcomes

Primary

Measure	Time frame
To compare the efficacy of weekly dose of 50 mg of Mifepristone and daily dose of 25 mg of Mifepristone in reduction of fibroid size and volumeTimepoint: 18 months	—

Secondary

Measure	Time frame
To compare the efficacy of weekly dose of 50 mg of Mifepristone and daily dose of 25 mg of Mifepristone in symptomatic improvementTimepoint: 18 months	—

Countries

India

Contacts

Public ContactSubhasri S

Sri Manakula Vinayagar Medical college and Hospital

niveog91@yahoo.com9994328253

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026